2009 Clinic IT Provider 
The Clinical Problem Solvers
DECEMBER 16, 2020
Nwamaka Eneanya and Jennifer Tsai to discuss the limitations and harms of race-based medicine in clinical practice. Our guests explain how we can incorporate race-conscious medicine in clinical settings, medical education, and biomedical/epidemiological research to responsibly recognize and address the harms of racial inequality.
Permanente Medicine
APRIL 16, 2025
NWP and TPMG are physician-led, independent Permanente Medical Groups who partner exclusively with Kaiser Foundation Health Plan to provide care for their patients in Oregon, southwest Washington, and Northern California. By collaborating clinically, sharing innovations, and supporting physicians and staff, NWP will improve quality of care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
FEBRUARY 26, 2024
This of course, make sense—after decades of experience implementing the Hatch-Waxman, Congress and FDA had learned a few new tricks by 2009/2010. To Boehringer’s first and most significant argument, that Congress intended the terms “strength” to match FDA’s interpretation in 2009—prior to the codification of the definition in 21 C.F.R.
FDA Law Blog
JANUARY 15, 2024
If you made it through the first 2 pages of the opinion, this Court’s answer is clear: FDA flagrantly violated the APA in denying those flavored e-cigarette applications due to the Agency’s utter failure to provide comprehensible instructions and consistent policies. FDA also directed manufacturers to produce detailed marketing plans.
FDA Law Blog
OCTOBER 24, 2023
By Dara Katcher Levy — Yesterday, FDA published a new Draft Guidance, “ Communications from Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers ” (SIUU Guidance or Draft Guidance).
FDA Law Blog
FEBRUARY 2, 2023
Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. adequate to justify the proposed clinical testing.” 21 U.S.C. § 355(i)(1)(A). 42 U.S.C. §
CDOCS
APRIL 14, 2021
& When I began practicing in 2009, I joined a practice that had a Redcam in the corner collecting dust.& & When I began practicing in 2009, I joined a practice that had a Redcam in the corner collecting dust.& & But, more importantly to me clinically, was the improvement in radiopacity.&
Expert insights. Personalized for you.
52 
Let's personalize your content